Keep up to date with life at the Babraham Research Campus. Explore the latest news, opinion and events from the campus, our stakeholders, partners and the companies based here.
Biotech firm bit.bio today announces the appointment of Dr Ramy Ibrahim, MD, as Chief Medical Officer. The addition of a Chief Medical Officer is in line with the company’s plans and commitment to transition into a clinical company.
Founded by Medicxi, Centessa Pharmaceuticals launched today as a novel asset-centric pharmaceutical company designed and built to advance a portfolio of highly validated programs.
PredictImmune, developers of pioneering prognostic tools for guiding treatment options and improving patient outcomes in immune-mediated diseases, is pleased to confirm the convening of its IBD Clinical Advisory Board (IBD CAB).
The partnership PetMedix announced with Boehringer Ingelheim earlier this month means that the Babraham Research Campus-based biotech company, freed from the constraints of having to develop a distribution operation, can now focus exclusively on science.
Artios Pharma, a leading DNA Damage Response (DDR) company developing a broad pipeline of precision medicines for the treatment of cancer, announces the appointment of Abid Ansari as Chief Financial Officer (CFO).
Babraham Bioscience Technologies Ltd (BBT), the organisation which oversees the development and day-to-day management of the Babraham Research Campus is pleased to welcome three new members to its board.
CELLINK and Atelerix announced today a partnership to bring to market Atelerix’s portfolio of innovative hydrogel biological encapsulation products, which preserve fragile biological samples for shipping at room temperature.
The Babraham Research Campus’ third cohort of Accelerate@Babraham life science start-ups went head-to-head on Wednesday afternoon (Nov 25th); competing for £10,000 additional funding generously donated by CMS Ventures.
Start Codon, a life science and healthcare business accelerator based in Cambridge, UK, today announced that it has closed Start Codon Fund I LP at £15 million ($20 million USD).
Inivata, a leader in liquid biopsy, today announces the appointment of Peter Collins as Chief Business Officer, effective immediately. Peter will be responsible for leading all business development, partnering and commercial activities.
Bicycle Therapeutics today announced that the first patient has been dosed in the Phase IIa expansion portion of the Phase I/IIa trial sponsored by Cancer Research UK, the world’s leading cancer charity dedicated to saving lives through research.
We are delighted to announce that we have entered into partnership with STORM Therapeutics, the leading biotechnology company focused on the discovery and development of small molecule therapies modulating RNA epigenetics, to explore new treatment options for people with epilepsy.
Atelerix has received a significant award under the UK Innovation and Science Seed Fund (UKI2S) Accelerator Programme from Innovate UK, the UK’s innovation agency. Funding will be used to explore scalable methods of human cell preservation, transport, and re-presentation for clinical applications.
Bicycle Therapeutics today announced that the first patient has been dosed in Oxurion’s Phase II study of THR-149, a novel Bicycle-based plasma kallikrein (PKal) inhibitor, in patients with diabetic macular edema (DME).
Barclays’ Entrepreneur Awards highlight and recognise entrepreneurs who are transforming their industries, the economy and society. Dr Andy Richards, CBE, has received the accolade in the Icon category which seeks to recognise entrepreneurs who have successfully turned their vision into reality.
Z Factor Ltd announced that the first human volunteer was dosed today with ZF874, its novel treatment for alpha-1-antitrypsin deficiency (AATD). AATD is a common genetic disorder, affecting around in 1 in 2000 people in Western countries.
Reflection Therapeutics, Cambridge-based developer of cell therapy against neuroinflammation, is pleased to announce the start of a major Innovate Smart Grant project co-funded by Innovate UK, the UK’s innovation agency.
Bicycle Therapeutics, a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the appointment of Dominic Smethurst, MA, MBChB, MRCP, MFPM as Chief Medical Officer.
The Babraham Research Campus-based molecular biology and microengineering company says the kit overcomes the drawbacks with current PCR-based testing and offers an economical solution suitable for deployment at businesses, care homes, airports and other key locations.
Working in close collaboration, scientists from the Tate Group, Imperial College London, and drug discovery and development company, Mission Therapeutics, have discovered the first exquisitely selective probe for a deubiquitylating enzyme (DUB).
BenevolentAI today announced the publication of further experimental data in support of its AI-derived hypothesis for baricitinib as a potential treatment for COVID-19 in the Journal: EMBO Molecular Medicine.
Nemesis Bioscience Ltd announced today that it had reached an agreement on terms for a two-year research collaboration with Shionogi & Co. Ltd. to further develop Nemesis Transmid Technology© for the treatment and/or prevention of hard-to-treat respiratory infections caused by Pseudomonas aeruginosa.
A new report published in June this year, confirms the Babraham Research Campus as one of the leading lights in the UK when it comes to delivering a supportive ecosystem to enable the commercialisation of life science research.
Atelerix announced today that it has significantly strengthened its leadership team with two experienced industry executives, who will help lead Atelerix in implementing its strategy to provide room temperature solutions for the shipping of therapeutic cells in the fast growing cellular therapy market.
Research led by an academic team from the University of Cambridge has demonstrated the benefits and outputs from the significant taxpayer investment into the Babraham Research Campus; evidencing the overall economic, social and scientific contribution the Campus makes to the UK economy.
Bicycle Therapeutics today announced that a research paper describing the mechanism of action for the Company’s first second-generation Bicycle Toxin Conjugate (BTC), BT5528, has been published in the American Association for Cancer Research (AACR) journal Molecular Cancer Therapeutics.
Crescendo Biologics today announce a Clinical Development Partnership to progress one of Crescendo’s novel bispecific Humabody® immunotherapies, CB213, into clinical trials targeting cancers of high unmet medical need.
MicrofluidX announces it has raised £1.4m in seed funding from leading seed investors UK Innovation & Science Seed Fund (UKI2S), Longwall Ventures and Moulton Goodies Limited with angel contributions from 88 Capital and Cambridge Angels.
F-star Therapeutics Ltd today announces the publication of preclinical data on the potent anti-tumor activity of FS120, a first-in-class dual-agonist tetravalent bispecific antibody targeting CD137 and OX40, in leading peer-reviewed journal Cancer Immunology Research.
After spending five-months on Campus the five winning StartUP@Babraham competition start-ups have come to the end of the programme. But for some, their journey at the Babraham Research Campus has only just begun.
Introduced by the Babraham Research Campus in 2018, the Accelerate@Babraham initiative supports ambitious early stage life science ventures within the active Babraham Research Campus community.
Sphere Fluidics today announced investment in the production and supply of its proprietary biocompatible surfactant, Pico-Surf™, for reliable and highly stable droplet generation and processing.
As a condition of the outline planning consent underpinning the BioMed@Babraham buildings, provision has been made on Campus for the installation of a permanent, publicly accessible artwork, which those on Campus and the local Babraham community can interact with and enjoy.
F-star Therapeutics today announces that the United States Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for FS120, F-star’s proprietary tetravalent bispecific antibody targeting CD137 and OX40.
PredictImmune today confirmed that it has entered into a commercial agreement with CCL, to provide PredictSURE IBD™ to clinicians and gastroenterologists in the UK, Ireland (non-exclusive), the Middle East and the Balkans (exclusively).
Sponsors of the Babraham Research Campus Accelerate@Babraham initiative, LifeArc, has announced the extension of its support, by releasing an additional £10,000 in the form of an award for the most progressed venture.
Bicycle Therapeutics today announced that the first patient has been dosed in the Phase I dose escalation of its Phase I/II study of BT5528, a BicycleToxin Conjugate (BTC) targeting tumour antigen EphA2, in patients with advanced solid tumours associated with EphA2 expression.
Bicycle Therapeutics today announced that new preclinical data from BT7480, a potent tumor-targeted immune cell agonist (TICA) targeting Nectin-4 and agonizing CD137 (4-1BB), will be presented at the Society for Immunotherapy of Cancer’s (SITC) 2019 Annual Meeting.
Bicycle Therapeutics today announced the appointment of Nigel Crockett, Ph.D., as the company’s Chief Business Officer, replacing Peter Leone. Dr. Crockett has more than 25 years of experience in global business development for biopharmaceutical companies.
Meet Ashok, researcher at BenevolentAI, at EMNLP for an oral presentation about his latest paper co-authored with Sia Togia: Biomedical relation extraction with pre-trained language representations and minimal task-specific architecture.
Bicycle Therapeutics today announced the presentation of updated data from a Phase I/IIa trial conducted in collaboration with Cancer Research UK and evaluating BT1718 in an unselected group of patients with advanced solid tumours.
Bicycle Therapeutics plc today announced that updated data from the Phase I dose escalation portion of the Phase I/IIa trial evaluating the Company’s lead asset BT1718 in patients with advanced solid tumors will be presented at the European Society of Medical Oncology (ESMO) 2019 Annual Congress.
The shortlist represents a showcase of the enormous talent in the Cambridge region across sectors from biotech to cleantech, artificial intelligence to agritech including companies from Babraham Research Campus.
BenevolentAI today announced that it has signed a Framework Collaboration Agreement with Novartis Pharma AG (“Novartis”) to leverage BenevolentAI’s technology platform to interrogate clinical trial and experimental data.
Bicycle Therapeutics plc, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycles®) product platform, today reported financial results for the second quarter ended June 30, 2019 and provided a clinical update.
Abzena announced it has successfully completed a technology transfer and scalability evaluation using the Synaffix technologies of GlycoConnect™ (antibody conjugation) and HydraSpace™ (highly polar spacer).
The Campus is going to be busy on Wednesday (May 15), with the one-day Babraham Investor Conference (BIC) immediately followed by the Accelerate@Babraham pitches, which gives five organisations the chance to work at Babraham for five months.
A long-term collaboration between AstraZeneca and BenevolentAI will bring the power of artificial intelligence and machine learning to bear in the hunt for new treatments for chronic kidney disease and idiopathic pulmonary fibrosis.
Chief Executive of Clinical and Strategic Partnerships at BenevolentAI Dr Jackie Hunter writes a piece for Pharma Boardroom on why the pharmaceutical industry has been slow to adopt artificial intelligence-based technologies and also makes a prediction for the industry’s future.
Today, BioMed Realty, the leading provider of real estate solutions to the life science community, announced its two newly developed Babraham Research Buildings in Cambridge are more than 50% let or under offer, including leases to PetMedix Ltd and Mission Therapeutics Ltd.
Bicycle Therapeutics today announced that it will collaborate with Oxford University’s Oxford Drug Discovery Institute (ODDI) to use Bicycle® technology for the development of novel therapeutics for dementia.
Abzena announced its Cambridge UK site has brought together its extensive discovery, immunogenicity assessment, protein engineering, formulation, bioassay and analytical expertise to launch a developability assessment and optimization service.
The annual competition gives up to five ventures the opportunity to win access to facilities, and take part in a fast-paced programme of support, led by a hand-picked group of experienced academic and commercial life science experts.
Bicycle Therapeutics today announced the successful completion of Oxurion’s Phase I clinical trial evaluating the safety and tolerability of a single intravitreal injection of THR-149, a novel Bicycle-based plasma kallikrein (PKal) inhibitor, in patients with diabetic macular edema (DME).
Bicycle Therapeutics today announced a collaboration with the Dementia Discovery Fund (DDF) to use Bicycle technology for the development of novel therapeutics for neurodegenerative diseases.
Bicycle Therapeutics today announced several key changes to its executive team, including the appointment of Peter B. Leone as Chief Business Officer and the promotion of Lee Kalowski, Chief Financial Officer, to the role of U.S. President.
Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycle™) product platform, announced today that Paul Beswick, Ph.D., Bicycle’s Director of UK Chemistry and IP, will present at the Research & Innovation 2019 conference.
Bicycle Therapeutics announced today that Bicycle scientists have been selected to present two oral presentations at the American Association for Cancer Research Annual Meeting in Atlanta.
Crescendo Biologics Ltd (Crescendo), the drug developer of novel, targeted T cell enhancing therapeutics, today announces that Stewart Kay has been appointed as the Company’s Chief Business Officer (CBO).
F-star Therapeutics Ltd today announces the appointment of Darlene Deptula-Hicks, MBA as Chief Financial Officer (CFO), succeeding Tolga Hassan, who is appointed to serve as F-star’s Chief Operating Officer.
Institute researchers are part of a world-first research project that will unravel how human embryos develop in the first weeks and months after fertilisation, improving our understanding of fertility, birth defects and regenerative medicine.
This event is mainly targeting protein and antibody researchers, bioanalysis research scientists and research groups with an interest in precision medicine, translational oncology and biomarkers.
Now in its 10th year, the one-day Babraham Investor Conference (BIC) will bring together like-minded investors focused on early-stage and scale-up life science and med-tech opportunities across the UK and Europe.
PredictImmune today announced that the UK's National Institute for Health and Care Excellence (NICE) has published a Medtech Innovation Briefing (MIB) on the use of PredictSURE IBD™ in the prognosis of inflammatory bowel disease.
A fast, accurate and low-cost test for blood potassium levels, which can be used at home and has the potential to improve the safety, health and lifestyle of tens of millions of people worldwide, is being developed by Kalium Diagnostics.
PhoreMost and Sentinel Oncology have expanded a collaboration to accelerate the progression of SOL686, a novel allosteric Polo-like kinase 1 (PLK1) inhibitor through preclinical development and IND enabling studies for the treatment of Glioma.
PhoreMost is set for a transformative phase of expansion that will create a revolutionary drug discovery business capable of influencing new treatments across a range of disease areas and featuring some of the world’s most influential Pharma players.
PolyProx Therapeutics will develop a new class of drugs, called Polyproxin™ molecules, that are able to selectively target tumour cells and trigger the natural degradation machinery contained within the cell to arrest tumour growth.
PredictImmune today announced the start of the PRECIOUS (Predicting Crohn’s and Colitis Outcomes in the United States) study, which it is jointly funding with the Crohn’s & Colitis Foundation.
The DAP evaluates new, cutting-edge medical diagnostic technologies, producing guidance to help people working in the NHS make efficient, cost-effective and consistent decisions about adopting new products.
PredictImmune today confirmed its latest patent grant in the US. The US patent is part of PredictImmune’s third family of intellectual property relating to methods for predicting autoimmune disease risk.
PredictImmune today confirmed that it has entered into an exclusive commercial partnership with KSL Biomedical (KSL), to commercialise and provide PredictImmune’s prognostic test for inflammatory bowel disease (IBD), PredictSURE IBD™, throughout North America.
PredictImmune, developers of pioneering prognostic tools for guiding treatment options and improving patient outcomes in immune-mediated diseases, today announced confirmation of its ISO 13485 certification.
PredictImmune, developers of pioneering prognostic tools for guiding treatment options and improving patient outcomes in immune-mediated diseases, is delighted to welcome James Clark as Chief Technology Officer.
PredictImmune today confirmed that it has entered into a commercial agreement with Addenbrooke’s hospital, part of Cambridge University Hospitals NHS Foundation Trust, to provide PredictSURE IBD™ to clinicians and gastroenterologists in the UK and Ireland.
With the second wave of its ‘Accelerate@Babraham’ life sciences bio-incubator programme well underway, the Babraham Research Campus has confirmed additional financial and mentoring support for the initiative from Mundipharma.
Sphere Fluidics, which is commercialising single cell analysis systems underpinned by its patented picodroplet technology, and Peak Analysis and Automation which supplies intelligent lab automation solutions, have announced a cell analysis collaboration.
Start Codon has been launched with funding from keystone investors including Cambridge Innovation Capital, Babraham Bioscience Technologies, Genentech, a member of the Roche Group, Dr Jonathan Milner and Dr Ian Tomlinson.
The first ever life science bio-incubator programme competition at the Babraham Research Campus, Accelerate@Babraham, has ended on a high for the competition winners with the promise of ongoing mentoring and an invitation to present at the renowned Babraham Investor Conference in 2019.
PredictImmune, developer of prognostic tools to guide treatment of patients with immune-mediated diseases, announced today that it has been awarded a grant of £100,000 by Innovate UK, the UK’s innovation agency.
PredictImmune today announced CE IVD (European Conformity In-Vitro Diagnostic Medical Devices) certification for its prognostic biomarker test for IBD, PredictSURE IBD™ - the first validated biomarker based prognostic test in inflammatory disease.
Additional company presentation will highlight preclinical research supporting the development of CD137 Bicycle® agonists as novel cancer immunotherapies.
Life science start-ups are invited to apply for one of up to five prizes that include a cash prize and access to the Babraham Research Campus bio-incubator facilities and much more...
PredictImmune, a developer of prognostic tools to guide treatment of patients with immune-mediated diseases, announced today that it has been awarded £4.3m by the Wellcome Trust.
The Babraham Research Campus is delighted to announce the appointment of Dr Karolina Zapadka as Business Acceleration Manager for the Babraham Research Campus’ bio-incubator and life science accelerator, Accelerate@Babraham.
One Nucleus is delighted to announce the appointment of Derek Jones as a Non-Executive Director. Derek is Chief Executive of Babraham Bioscience Technologies Ltd (BBT), the organisation responsible for the development and management of the Babraham Research Campus.
Accelerate@Babraham is designed to support the earliest stages of new life-science ventures, by providing easy-access laboratory and office space, (the ‘bio-incubator’) together with supporting programmes (the ‘accelerator’).
Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, provides an update on its UK and US facilities.
In October 2017, we were delighted to launch our partnership with BioMed Realty. This collaboration will see a new 108,000 square foot scale-up research space for growing bioscience-based companies built on site. Watch the launch video to find out more.
Biosceptre has received over £8M into its’ series A raise which will be used to resource the next stage of the companies’ development; progression into the clinic of Biosceptre’s first systemic products against novel oncology target nfP2X7.
Sixth Element Capital LLP (6EC), a UK based fund manager established to manage investments for the £70 million CRT Pioneer Fund, announces a £3 million investment in NeoPhore Ltd, a spin out from Cambridge, UK based PhoreMost Ltd.
Evelyn Warner, Editor of LaBiotech.eu, a leading digital media publisher covering the European Biotech industry interviews Derek Jones, Chief Executive of Babraham Bioscience Technologies (BBT) to talk about strategies for biotech startups.
Behind every successful meeting, lies the perfect venue. This can often be overlooked while you’re focussing on the smaller details of the day. If you’re responsible for coordinating your organisation’s next conference, or seminar, choosing the right space will be crucial to it's success.
As part of the UK’s £64B life sciences sector Babraham Bioscience Technologies, (BBT), welcomes the publication of Prof. Sir John Bell’s Life Science Industrial Strategy to the UK Government.
Cambridge Epigenetix (CEGX) and NuGEN Technologies, today announced that they have entered into a partnership agreement to integrate the CEGX TrueMethyl technology for oxidative bisulfite sequencing (oxBS-Seq) with NuGEN’s innovative NGS library preparation kits.
We are keen to promote the work that we do, telling the story of the Babraham Research Campus and the organisations that are based here. If you are interested in running a story, using our images or films or want to discuss an interview or potential collaboration opportunity we would be very pleased to hear from you. Please contact Sarah at Limewash to discuss your requirements
Sarah Brereton, Director, Limewash
01223 813 557, firstname.lastname@example.org
(+44) 1223 496 000
Babraham Bioscience Technologies Ltd
Babraham Research Campus
CB22 3AT, United Kingdom
01223 813 557